Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice

M.C.T. van Zeijl, A.J.M. van den Eertwegh, M.W.J.M. Wouters, L.C. de Wreede, M.J.B. Aarts, F.W.P.J. van den Berkmortel, J.W.B. de Groot, G.A.P. Hospers, E. Kapiteijn, D. Piersma, R.S. van Rijn, K.P.M. Suijkerbuijk, A.J. ten Tije, A.A.M. van der Veldt, G. Vreugdenhil, J.J.M. van der Hoeven, J.B.A.G. Haanen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)317-326
Number of pages10
JournalInternational Journal of Cancer
Volume150
Issue number2
Early online date2 Oct 2021
DOIs
Publication statusPublished - 15 Jan 2022

Keywords

  • advanced melanoma
  • anti-PD-1
  • discontinuation
  • immunotherapy
  • real-world
  • METASTATIC MELANOMA
  • SURVIVAL
  • PEMBROLIZUMAB
  • IPILIMUMAB

Cite this